Malaria category-wise clinical characteristics of enrolled subjects.

MM = Mild malaria, SM-S = severe malaria survivors, CM-S = cerebral malaria survivors, CM-NS# = cerebral malaria non-survivors (57 were CM-NS and 5 were SM-NS (severe malaria non-survivors); Severe malaria (SM) cases had no cerebral signs. MCS = Multiple complication score; number of observations – creatinine/urea (MM = 11, SM-S = 9, CM-S = 38, CM-NS = 18); bilirubin in adults (MM = 17, SM-S = 11, CM-S = 43, CM-NS = 22); TLC (MM = 46, SM-S = 20, CM-S = 68, CM-NS = 18); p values of numeric variables shown in bold were calculated by ANOVA and others were by Kruskal-Wallis rank test. * p value excluding MM group; **p value = 0.0082 (kruskal-wallis) between CM-S and CM-NS. Outcome of 8 cerebral malaria cases and 2 severe malaria cases is unknown and thus have not been included in analysis. IQR = Inter-quartile range. N/A = Not applicable.Malaria category-wise clinical characteristics of enrolled subjects.MM为轻型疟疾（Mild malaria），SM-S为重型疟疾存活者（severe malaria survivors），CM-S为脑型疟疾存活者（cerebral malaria survivors），CM-NS#为脑型疟疾非存活者（cerebral malaria non-survivors），其中57例为CM-NS，另有5例为SM-NS（重型疟疾非存活者，severe malaria non-survivors）；所有重型疟疾（SM）病例均无脑部受累体征。MCS为多并发症评分（Multiple complication score）；观测样本量如下：肌酐/尿素指标（MM组=11，SM-S组=9，CM-S组=38，CM-NS组=18）；成人血清胆红素指标（MM组=17，SM-S组=11，CM-S组=43，CM-NS组=22）；总白细胞计数（Total Leucocyte Count, TLC）（MM组=46，SM-S组=20，CM-S组=68，CM-NS组=18）；以粗体标注的数值变量的p值通过方差分析（ANOVA）计算，其余变量的p值通过Kruskal-Wallis秩和检验计算。*代表排除MM组后的p值；**CM-S组与CM-NS组间的Kruskal-Wallis检验p值为0.0082。另有8例脑型疟疾病例及2例重型疟疾病例的临床转归未知，因此未纳入本次分析。IQR为四分位距（Inter-quartile range）；N/A为不适用（Not applicable）。本数据集涵盖入组受试者按疟疾分类的临床特征。